|
[1]MUHLBERGER N, SCHWARZER R, LETTMEIER B, et al.HCV-related burden of disease in Europe:a systematic assessment of incidence, prevalence, morbidity, and mortality[J].BMC Public Health, 2009, 9:34.
|
|
[2]GOLEMBA MD, DI LELLO FA, BESSONE F, et al.High prevalence of hepatitis C virus genotype 1b infection in a small town of Argentina.Phylogenetic and Bayesian coalescent analysis[J].PLoS One, 2010, 5 (1) :e8751.
|
|
[3]SWAIN MG, LAI MI, SHIFFMAN ML, et al.A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin[J].Gastroenterology, 2010, 139 (5) :1593-1601.
|
|
[4]THURSZ M, YEE L, KHAKOO S.Understanding the host genetics of chronic hepatitis B and C[J].Semin Liver Dis, 2011, 31 (2) :115-127.
|
|
[5]XIA WJ, YE X, FU YS, et al.Study on association between hepatitis C-6a and HLA-Ⅰallele in Guangzhou area[J].Chin J Immunol, 2011, 27 (4) :330-333. (in Chinese) 夏文杰, 叶欣, 付涌水, 等.广州地区人类白细胞抗原-Ⅰ类与丙型肝炎病毒-6a型感染相关性的研究[J].中国免疫学杂志, 2011, 27 (4) :330-333.
|
|
[6]MURPHY D, CHAMBERLAND J, DANDAVINO R, et al.A new genotype of hepatitis C virus originating from central Africa[J].Hepatology, 2007, 46 (Suppl 1) :623a.
|
|
[7]GE D, FELLAY J, THOMPSON AJ, et al.Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance[J].Nature, 2009, 461 (7262) :399-401.
|
|
[8]SARRAZIN C, SUSSER S, DOEHRING A, et al.Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients[J].J Hepatol, 2011, 54 (3) :415-421.
|
|
[9]ANDRZEJ C, MONIKA BJ, IWONA SK, et al.IL28B polymorphism as a predictor of antiviral response in chronic hepatitis C[J].World J Gastroenterol, 2012, 18 (35) :4892-4897.
|
|
[10]SUPPIAH V, MOLODVAN M, AHIENSTIEL G, et al.IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy[J].Nature Genetics, 2009, 4 (10) :1100-1104.
|
|
[11]TANAKA Y, NISHIDA N, SUGIYAMA M, et al.Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C[J].Nature Genetics, 2009, 41 (10) :1105-1109.
|
|
[12]RAUCH A, KUTALIK Z, DESCOMBES P, et al.Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure:a genome-wide association study[J].Gastroenterology, 2010, 138 (4) :1338-1345.
|
|
[13]KAWAOKA T, HAYES CN, OHISHI W, et al.Predictive value of the IL28B polymorphism on the effect of interferon therapy in chronic hepatitis C patients with genotypes 2a and 2b[J].J Hepatol, 2011, 54 (3) :408-414.
|
|
[14]EURICH D, BOAS-KNOOP S, RUEHI M, et al.Relationship between the interleukin-28b gene polymorphism and the histological severity of hepatitis C virus-induced graft inflammation and the response to antiviral therapy after liver transplantation[J].Liver Transplantation, 2011, 17 (3) :289-298.
|
|
[15]FRED P, JONATHAN MC, BRUCE R, et al.Boceprevir for untreated chronic HCV genotype 1 infection[J].N Engl J Med, 2011, 364 (13) :1195-1206.
|
|
[16]JACOSON IM, CATLETT I, MARCELLIN P, et al.Telaprevir substantially improved SVR rates across all IL28B genotypes in the advance trial[J].J Hepatol, 2011, 54 (Suppl 1) :s542-s543.
|
|
[17]JENSEN DM, PLO S.IL28B genetic polymorphism testing in the era of direct acting antivirals therapy for chronic hepatitis C:ten years too late?[J].Liver Int, 2012, 32 (Suppl 1) :S74-S78.
|
|
[18]THOMAS DL, THIO CL, MARTIN MP, et al.Genetic variation in IL28B and spontaneous clearance of hepatitis C virus[J].Nature, 2009, 461 (7265) :798-801.
|
|
[19] RAUCH A, KUTALIK Z, DESCOMBES P, et al.Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure:a genome-wide association study[J].Gastroenterology, 2010, 138 (4) :1338-1345.
|
|
[20]CONG R, TONG XF, LIU SD, et al.Genetic variation in IL-28B and spontaneous clearance of hepatitis C virus[J].J Capit Med Univ, 2012, 33 (3) :326-329.丛瑞, 佟小非, 刘三都, 等.白细胞介素28B (IL-28B) 基因多态性与丙型肝炎病毒 (HCV) 感染者自发清除的相关性[J].首都医科大学学报, 2012, 33 (3) :326-329.
|
|
[21]LIU L, FISHER BE, THOMAS DL, et al.Spontaneous clearance of primary acute hepatitis C virus infection correlated with high initial viral RNA level and rapid HVR1 evolution[J].Hepatology, 2012, 55 (6) :1684-1691.
|
|
[22]BES M, SAULEDA S, CAMPOS-VARELA I, et al.IL28B genetic variation and hepatitis C virus specific CD4+T-cell responses in anti-HCV-positive blood donors[J].J Viral Hepatitis, 2012, 19 (12) :867-871.
|
|
[23]BOCHUD PY, BIBERT S, KUTALIK Z, et al.IL28B alleles associated with poor hepatitis C (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotype[J].Hepatology, 2012, 55 (2) :384-394.
|
|
[24]CONG R, TONG XF, SUN YM, et al.Association between IL-28B gene polymorphisms and liver fibrosis in patients with chronic hepatitis C[J].Infect Dis Infor, 2012, 25 (2) :93-95.丛瑞, 佟小非, 孙亚朦, 等.IL-28B基因多态性与慢性丙型肝炎患者肝纤维化的相关性研究[J].传染病信息, 2012, 25 (2) :93-95.
|
|
[25]ROMERO AI, AGGING ML, WESTIN J, et al.Interferon (IFN) -gamma-inducible protein-10:association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha2a and ribavirin for chronic hepatitis C virus infection[J].J Infect Dis, 2006, 194 (7) :895-903.
|
|
[26]ASKARIEH G, ALSIO A, PUGNALE P, et al., Systemic and intrahepatic interferon-gamma-inducible protein 10 kDa predicts the first-phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis C[J].Hepatology, 2010, 51 (5) :1523-1530.
|
|
[27]ASKARIEH G, ALSIO A, PUGNALE P, et al.Systemic and intrahepatic interferon-gamma-inducible protein 10 kDa predicts the first-phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis C[J].Hepatology, 2010, 51 (5) :1523-1530.
|
|
[28]FATTOVICH G, COVOLO L, BIBERT S, et al.IL28B polymorphisms, IP-10 and viral load predict virological response to therapy in chronic hepatitis C[J].Aliment Pharmacol Ther, 2011, 33 (10) :1162-1172.
|
|
[29]ZAMPINO R, INGROSSO D, DURANTE-MANGONI E, et al.Microsomal triglyceride transfer protein (MTP) -493G/T gene polymorphism contributes to fat liver accumulation in HCV genotype 3infected patients[J].J Viral Hepat, 2008, 15 (10) :740-746.
|
|
[30]VALENTI L, RUMI M, GALMOZZI E, et al.Patatin-like phospholipase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C[J].Hepatology, 2011, 53 (3) :791-799.
|
|
[31]KNAPP S, WARSHOW U, HEGAZY D, et al.Consistent beneficial effects of killer cell immunoglobulin-like receptor 2DL3 and group 1 human leukocyte antigen-C following exposure to hepatitis C virus[J].Hepatology, 2010, 51 (4) :1168-1175.
|
|
[32]VIDAL-CASTINEIRA JR, LOPEZ-VAZQUEZ A, DIAZ-PENA R, et al.Effect of killer immunoglobulin-like receptors in the response to combined treatment in patients with chronic hepatitis C virus infection[J].J Virol, 2009, 84 (1) :475-481.
|
|
[33]AHLENSTIEL G, MARTIN MP, GAO X, et al.Distinct KIR/HLA compound genotypes affect the kinetics of human antiviral natural killer cell responses[J].J Clin Invest, 2008, 118 (3) :1017-1026.
|
|
[34]AHLENSTIEL G, MARTIN MP, GAO X, et al.Distinct KIR/HLA compound genotypes affect the kinetics of human antiviral natural killer cell responses[J].J Clin Invest, 2008, 118 (3) :1017-1026.
|
|
[35]ISHIDA C, LKEBUCHI Y, OKAMOTO K, et al.Functional gene polymorphisms of interleukin-10 are associated with liver disease progression in Japanese patients with hepatitis C virus infection[J].Inter Med, 2011, 50 (7) :659-666.
|
|
[36]FELLAY J, THOMPSON AJ, Ge D, et al.ITPA gene variants protect against anemia in patients treated for chronic hepatitis C[J].Nature, 2010, 464 (7287) :405-408.
|
|
[37] THOMPSON AJ, SANTORO R, PIAZZOLLA V, et al.Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR[J].Hepatology, 2011, 53 (2) :389-395.
|
|
[38]THOMPSON AJ, SANTORO R, PIAZZOLLA V, et al.Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR[J].Hepatology, 2011, 53 (2) :389-395.
|
|
[39]OCHI H, MAEKAWA T, ABE H, et al.ITPA polymorphism affects ribavirin-induced anemia and outcomes of therapy-a genome-wide study of Japanese HCV virus patients[J].Gastroenterology, 2010, 139 (4) :1190-1197.
|
DownLoad: